Freenome Targets 50M Patient Market with SimpleScreen CRC Blood Test

Key Facts

1Freenome's SimpleScreen CRC test is licensed to Abbott with potential milestone payments of up to $700 million.

2The company holds a $410 million cash reserve and targets a market of 50 million unscreened patients.

Amid a growing shift toward AI-driven early cancer detection, Freenome is positioning itself as a key player in the biotechnology and diagnostics sector. According to reports, the company has licensed its SimpleScreen CRC test to Abbott, a deal that includes potential milestone payments of up to $700 million. This partnership aims to provide a patient-friendly, blood-based alternative to traditional screening methods, specifically targeting unscreened populations.

The company's growth strategy focuses on a massive total addressable market (TAM) of 50 million patients who are currently not screened for colorectal cancer. These ambitions are backed by a solid financial foundation, with Freenome holding a $410 million cash reserve to fund its operations and the development of its multiomics platform. Per market data, this strong liquidity position and strategic licensing are intended to capture a significant share of the early detection market.

Regarding stock performance, FRNM closed at $16.6 on September 21, 2026, having reached a day high of $17.5. Investors are now watching for upcoming clinical catalysts to gauge the market penetration of the SimpleScreen test. On the macroeconomic front, market participants are monitoring US Initial Jobless Claims scheduled for later this week, which may influence broader risk sentiment in the biotech industry.